Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

European Commission to Review Luspatercept for Anemia-Associated, Non-Transfusion Dependent Beta Thalassemia

January 27th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of luspatercept for the treatment of patients with anemia associated with non–transfusion dependent beta thalassemia.

Steroid Refractory Acute GvHD and REACH Trials

January 27th 2023

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options

January 27th 2023

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

The FDA has granted a fast track designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome.

First-Line Treatment Options for Lower-Risk MDS

January 26th 2023

Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.

Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms

January 26th 2023

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

Considerations for MDS Pathology and Risk Status Reporting

January 26th 2023

A focused discussion on best practices for MDS pathology and risk status reporting in both community and academic center settings.

An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation

January 26th 2023

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Lessons Learned From the MajesTEC-1 Trial of Teclistamab

January 25th 2023

In this third episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, highlights the efficacy and safety profile of teclistamab, a BCMA-directed bispecific T-cell engager, in heavily pretreated multiple myeloma.

Trial Updates on Low-Dose Lenalidomide and Luspatercept

January 25th 2023

An overview of updates from the Sintra-REV trial of low-dose lenalidomide, and data from COMMANDS, MEDALIST, and real-world studies on luspatercept.

IMerge: Updated Safety and Efficacy Data on Imetelstat for Lower-Risk MDS

January 25th 2023

Hematology experts highlight recent data updates from the IMerge trial on the telomerase inhibitor imetelstat, which is being studied for lower-risk MDS.

Current Classifications of Acute Myeloid Leukemia

January 24th 2023

Expert perspectives on current classification strategies in acute myeloid leukemia and how these guidelines make use of molecular markers.

Overview of Acute Myeloid Leukemia

January 24th 2023

Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.

Prophylactic Measures to Prevent Tumor Lysis Syndrome

January 24th 2023

Expert perspectives on prophylactic measures to prevent tumor lysis syndrome in patients receiving therapy for cancer.

Role of a Multidisciplinary Healthcare Team to Manage Tumor Lysis Syndrome

January 24th 2023

Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.

Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma

January 23rd 2023

Craig Sauter, MD, discusses the rationale for investigating maintenance pembrolizumab following autologous stem cell transplant in patients with T-cell NHL and explained some of the potential challenges of investigating this regimen in a larger prospective trial in this patient population.

Future of Acute GvHD Prevention

January 20th 2023

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Clinical Implications of the Phase III BMT CTN 1703 Trial

January 20th 2023

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

UK’s MHRA Approves Zanubrutinib for CLL and MZL

January 19th 2023

The Medicines and Healthcare Products Regulatory Agency has approved zanubrutinib in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia and the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20–based therapy.

Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy

January 19th 2023

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.